Tuberculosis diagnostics and biomarkers: Needs, challenges, recent advances, and opportunities

Journal of Infectious Diseases

Volumn 205, Issue SUPPL. 2, 2012, Pages

  McNerney, Ruth ^a   Maeurer, Markus ^b   Abubakar, Ibrahim ^c,d   Marais, Ben ^e   McHugh, Timothy D ^f   Ford, Nathan ^g   Weyer, Karin ^h   Lawn, Steve ^a,i   Grobusch, Martin P ^j   Memish, Ziad ^k   Squire, S Bertel ^l   Pantaleo, Giuseppe ^m   Chakaya, Jeremiah ^n,o   Casenghi, Martina ^g   Migliori, Giovanni Batista ^p   Mwaba, Peter ^q   Zijenah, Lynn ^r   Hoelscher, Michael ^s   Cox, Helen ^g,t   Swaminathan, Soumya ^u   Kim, Peter S ^v   Schito, Marco ^v,w   Harari, Alexandre ^m   Bates, Matthew ^f,m   Schwank, Samana ^f,x   O'Grady, Justin ^f,x   Pletschette, Michel ^y   Ditui, Lucica ^z   Atun, Rifat ^aa,ab   Zumla, Alimuddin ^f,x   more..

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^e UNIVERSITY OF SYDNEY   (Australia)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g MÉDECINS SANS FRONTIÈRES   (Switzerland)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ UNIVERSITY OF CAPE TOWN   (South Africa)

^j UNIVERSITY OF AMSTERDAM   (Netherlands)

^k ALFAISAL UNIVERSITY   (Saudi Arabia)

^l LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^m LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁿ Kenya Medical Research Institute   (South Africa)

^o MINISTRY OF HEALTH   (Kenya)

^p IRCCS   (Italy)

^q MINISTRY OF HEALTH   (Zambia)

^r UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^s UNIVERSITY OF MUNICH   (Germany)

^t MONASH UNIVERSITY   (Australia)

^u NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^v NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^w The Henry M Jackson Foundation for the Advancement of Military Medicine   (United States)

^x UNIVERSITY OF ZAMBIA   (Zambia)

^y EUROPEAN COMMISSION   (Belgium)

^z Stop TB Partnership   (United Kingdom)

^aa The Global Fund   (Switzerland)

^ab IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; INTERLEUKIN 2; ISONIAZID; LINEZOLID; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; TUMOR NECROSIS FACTOR ALPHA;

ASPIRATION BIOPSY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE COURSE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FLOW CYTOMETRY; FUTUROLOGY; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH CARE NEED; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LIGHT EMITTING DIODE; MICROSCOPY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; T LYMPHOCYTE; TUBERCULOSIS; TUBERCULOSIS CONTROL; URINALYSIS;

ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; BIOLOGICAL MARKERS; DRUG RESISTANCE, BACTERIAL; HUMANS; TUBERCULOSIS;

EID: 84860356467     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir860     Document Type: Review

References (94)

1. Lawn SD, Zumla AI. Tuberculosis. Lancet 2011; 378:57-72.
2. World Health Organization. WHO report. Global tuberculosis control. Geneva: World Health Organization, 2011.
3. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: World Health Organization, 2010.
4. Zumla A, Abubakar I, Raviglione M, et al. Drug-resistant tuberculosisdcurrent dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012; 205(Suppl 2):S228-40.
5. Zumla A, Atun R, Maeurer M, et al. Viewpoint: scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Trop Med Int Health 2011; 16:79-83.
6. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282:677-86.
7. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health 2008; 8:15.
8. Cuevas L, Browning R, Bossuyt P, et al. Evaluation of tuberculosis diagnostics in children: 2 methodological issues for conducting and reporting research evaluations of tuberculosis diagnostics for itrathoracic tuberculosis. J Infect Dis 2012; 205(Suppl 2):S209-15.
9. Cuevas LE. The urgent need for new diagnostics for symptomatic tuberculosis in children. Indian J Pediatr 2011; 78:449-55.
10. Temple B, Ayakaka I, Ogwang S, et al. Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis 2008; 47:1126-34.
11. Weyer K, Carai S, Nunn P. TB diagnosticsdwhat does the world really need? J Infect Dis 2011; 204 (Suppl 4):S1196-202.
12. Dowdy DW, Cattamanchi A, Steingart KR, Pai M. Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. PLoS Med 2011; 8:e1001063.
13. World Health Organization. World health statistics 2010. Geneva: World Health Organization, 2010.
14. Long Q, Li Y, Wang Y, et al. Barriers to accessing TB diagnosis for rural-to-urban migrants with chronic cough in Chongqing, China: a mixed methods study. BMC Health Serv Res 2008; 8:202.
15. Liu X, Thomson R, Gong Y, et al. How affordable are tuberculosis diagnosis and treatment in rural China? An analysis from community and tuberculosis patient perspectives. Trop Med Int Health 2007; 12:1464-71.
16. Kemp JR, Mann G, Simwaka BN, Salaniponi FM, Squire SB. Can Malawi's poor afford free tuberculosis services? Patient and household costs associated with a tuberculosis diagnosis in Lilongwe. Bull World Health Organ 2007; 85:580-5.
17. Squire SB, Belaye AK, Kashoti A, et al. "Lost" smear-positive pulmonary tuberculosis cases: where are they and why did we lose them? Int J Tuberc Lung Dis 2005; 9:25-31.
18. Keeler E, Perkins MD, Small P, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature 2006; 444(Suppl 1):49-57.
19. World Health Organization. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis. Geneva: World Health Organization, 2010.
20. Lin HH, Langley I, Mwenda R, et al. A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools. Int J Tuberc Lung Dis 2011; 15:996-1004.
21. Mann G, Squire SB, Bissell K, et al. Beyond accuracy: creating a comprehensive evidence base for TB diagnostic tools. Int J Tuberc Lung Dis 2010; 14:1518-24.
22. Squire SB, Ramsay AR, van den Hof S, et al. Making innovations accessible to the poor through implementation research. Int J Tuberc Lung Dis 2011; 15:862-70.
23. Marais BJ, Raviglione MC, Donald PR, et al. Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet 2010; 375:2179-91.
24. McNerney R, Daley P. Towards a point-of-care test for active tuberculosis: obstacles and opportunities. Nat Rev Microbiol 2011; 9:204-13.
25. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375:1920-37.
26. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011; 11: 343-54.
27. O'Grady J, Maeurer M, Mwaba P, et al. New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr Opin Pulm Med 2011; 17:134-41.
28. John SH, Kenneth J, Gandhe AS. Host biomarkers of clinical relevance in tuberculosis: review of gene and protein expression studies. Biomarkers 2011; Epub ahead of print.
29. Lemaire JF, Casenghi M. New diagnostics for tuberculosis: fulfilling patient needs first. J Int AIDS Soc 2010; 13:40.
30. Betsou F, Parida S, Guillerm M. Infectious diseases biobanking as a catalyst towards personalized medicine: M. tuberculosis paradigm. Tuberculosis (Edinb) 2011; 91:524-32.
31. Nathanson CM, Cuevas LE, Cunningham J, et al. The TDR Tuberculosis Specimen Bank: a resource for diagnostic test developers. Int J Tuberc Lung Dis 2010; 14:1461-7.
32. Steingart KR, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6:664-74.
33. Cuevas LE, Al-Sonboli N, Lawson L, et al. LED fluorescence microscopy for the diagnosis of pulmonary tuberculosis: a multi-country cross-sectional evaluation. PLoS Med 2011; 8:e1001057.
34. Cuevas LE, Yassin MA, Al-Sonboli N, et al. A multi-country noninferiority cluster randomized trial of frontloaded smear microscopy for the diagnosis of pulmonary tuberculosis. PLoS Med 2011; 8:e1000443.
35. Steingart KR, Henry M, Laal S, et al. A systematic review of commercial serological antibody detection tests for the diagnosis of extrapulmonary tuberculosis. Thorax 2007; 62:911-8.
36. World Health Organization. Commercial serodiagnostic tests for diagnosis of tuberculosis: policy statement. Geneva: World Health Organization, 2011.
37. Diel R, Goletti D, Ferrara G, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37:88-99.
38. Sester M, Sotgiu G, Lange C, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and metaanalysis. Eur Respir J 2011; 37:100-11.
39. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011; 56:230-8.
40. European Centre for Disease Prevention and Control. Use of interferongamma release assays in support of tuberculosis diagnosis. Stockholm: European Centre for Disease Prevention and Control, 2011.
41. World Health Organization. Use of interferon-g release assays (IGRAs) in TB control in low and middle-income settings. Geneva: World Health Organization, 2010.
42. National Institute for Health and Clinical Excellence. NICE clinical guideline 117. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: National Institute for Health and Clinical Excellence, 2011.
43. Harari A, Rozot V, Enders FB, et al. Dominant TNF-alpha1 Mycobacterium tuberculosis-specific CD41 T cell responses discriminate between latent infection and active disease. Nat Med 2011; 17:372-6.
44. Axelsson-Robertson R, Ahmed RK, Weichold FF, et al. Human leukocyte antigens A*3001 and A*3002 show distinct peptidebinding patterns of the Mycobacterium tuberculosis protein TB10.4: consequences for immune recognition. Clin Vaccine Immunol 2011; 18:125-34.
45. Hohn H, Kortsik C, Tully G, et al. Longitudinal analysis of Mycobacterium tuberculosis 19-kDa antigen-specific T cells in patients with pulmonary tuberculosis: association with disease activity and cross-reactivity to a peptide from HIVenv gp120. Eur J Immunol 2003; 33:1613-23.
46. Tully G, Kortsik C, Hohn H, et al. Highly focused T cell responses in latent human pulmonary Mycobacterium tuberculosis infection. J Immunol 2005; 174:2174-84.
47. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-15.
48. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010; 48:229-37.
49. Banada PP, Sivasubramani SK, Blakemore R, et al. Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. J Clin Microbiol 2010; 48:3551-7.
50. Blakemore R, Story E, Helb D, et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 2010; 48: 2495-501.
51. Armand S, Vanhuls P, Delcroix G, Courcol R, Lemaitre N. Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan realtime PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. J Clin Microbiol 2011; 49:1772-6.
52. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377:1495-505.
53. Marlowe EM, Novak-Weekley SM, Cumpio J, et al. Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol 2011; 49:1621-3.
54. Theron G, Peter J, van Zyl-Smit R, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011; 184: 132-40.
55. Lawn S, Nicol M. Xpert MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 2011; 6:1067-82.
56. Nicol MP, Workman L, Isaacs W, et al. A descriptive study of the accuracy of the Xpert MTB/RIF test for diagnosis of pulmonary tuberculosis in hospitalized children in a high HIV prevalence area. Lancet Infect Dis 2011; 11:819-24.
57. Lawn SD, Brooks SV, Kranzer K, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011; 8:e1001067.
58. World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational "How-to"; practical considerations. Geneva: World Health Organization, 2011.
59. Ferrara G, O'Grady J, Zumla A, Maeurer M. Xpert MTB/RIF test for tuberculosis. Lancet 2011; 378:482; author reply 82-3.
60. Morris K. Xpert TB diagnostic highlights gap in point-of-care pipeline. Lancet Infect Dis 2010; 10:742-3.
61. Mwaba P, McNerney R, Grobusch MP, et al. Achieving STOP TB Partnership goals: perspectives on development of new diagnostics, drugs and vaccines for tuberculosis. Trop Med Int Health 2011; 16:819-27.
62. Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W. XpertMTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resourcelimited countries: hype or hope? Expert Rev Mol Diagn 2010; 10: 937-46.
63. FIND. Performance of Xpert MTB/RIF version G4 assay. Geneva: Foundation for Innovative New Diagnostics; 2011.
64. Nicol MP, Zar HJ. New specimens and laboratory diagnostics for childhood pulmonary TB: progress and prospects. Paediatr Respir Rev 2011; 12:16-21.
65. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 2005; 365:130-4.
66. Chow F, Espiritu N, Gilman RH, et al. La cuerda dulceda tolerability and acceptability study of a novel approach to specimen collection for diagnosis of paediatric pulmonary tuberculosis. BMC Infect Dis 2006; 6:67.
67. Wilson S, Lane A, Rosedale R, Stanley C. Concentration of Mycobacterium tuberculosis from sputum using ligand-coated magnetic beads. Int J Tuberc Lung Dis 2010; 14:1164-8.
68. Graham S, et al. Evaluation of tuberculosis diagnostics in children: 1. proposed clinical case definitions for classification of intra-thoracic tuberculosis disease. J Infect Dis 2012; 205(Suppl 2):S199-208.
69. Mudenda V, Lucas S, Shibemba A, et al. Tuberculosis and tuberculosis/HIV/AIDS-associated mortality in Africa: the urgent need to expand and invest in routine and research autopsies. J Infect Dis 2012; 205(Suppl 2):S340-6.
70. Vadwai V, Boehme C, Nabeta P, Shetty A, Alland D, Rodrigues C. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? J Clin Microbiol 2011; 49:2540-5.
71. Wright CA, Hesseling AC, Bamford C, Burgess SM, Warren R, Marais BJ. Fine-needle aspiration biopsy: a first-line diagnostic procedure in paediatric tuberculosis suspects with peripheral lymphadenopathy? Int J Tuberc Lung Dis 2009; 13:1373-9.
72. Wright CA, Warren RM, Marais BJ. Fine needle aspiration biopsy: an undervalued diagnostic modality in paediatric mycobacterial disease. Int J Tuberc Lung Dis 2009; 13:1467-75.
73. van Wyk AC, Marais BJ, Warren RM, van Wyk SS, Wright CA. The use of light-emitting diode fluorescence to diagnose mycobacterial lymphadenitis in fine-needle aspirates from children. Int J Tuberc Lung Dis 2011; 15:56-60.
74. Rose PC, Schaaf HS, Marais BJ, Gie RP, Stefan DC. Value of bone marrow biopsy in children with suspected disseminated mycobacterial disease. Int J Tuberc Lung Dis 2011; 15:200-4, i.
75. Oberhelman RA, Soto-Castellares G, Caviedes L, et al. Improved recovery of Mycobacterium tuberculosis from children using the microscopic observation drug susceptibility method. Pediatrics 2006; 118:e100-6.
76. Marais BJ, Gie RP, Hesseling AC, et al. A refined symptom-based approach to diagnose pulmonary tuberculosis in children. Pediatrics 2006; 118:e1350-9.
77. Marais BJ, Pai M. New approaches and emerging technologies in the diagnosis of childhood tuberculosis. Paediatr Respir Rev 2007; 8: 124-33.
78. Marais S, Pepper DJ, Marais BJ, Torok ME. HIV-associated tuberculous meningitisddiagnostic and therapeutic challenges. Tuberculosis (Edinb) 2010; 90:367-74.
79. Green C, Huggett JF, Talbot E, Mwaba P, Reither K, Zumla AI. Rapid diagnosis of tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid amplification methods. Lancet Infect Dis 2009; 9:505-11.
80. Peter J, Green C, Hoelscher M, Mwaba P, Zumla A, Dheda K. Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin Pulm Med 2010; 16: 262-70.
81. Minion J, Leung E, Talbot E, Dheda K, Pai M, Menzies D. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur Respir J 2011; 38:1398-405.
82. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 2009; 23:1875-80.
83. Shah M, Variava E, Holmes CB, et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J Acquir Immune Defic Syndr 2009; 52:145-51.
84. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIVassociated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2011; E-Pub Ahead of Print Oct 17.
85. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47:1767-72.
86. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32:1165-74.
87. Moore DA, Evans CA, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355:1539-50.
88. World Health Organization. New laboratory diagnostic tools for tuberculosis control. Geneva: World Health Organization, 2008.
89. World Health Organization. Report of the 9th meeting: WHO strategic and technical advisory group for tuberculosis. Geneva: World Health Organization, 2009.
90. Treatment Action Group. 2009 report on tuberculosis research funding Trends, 2005-2008. New York: Treatment Action Group, 2009.
91. Kunnath-Velayudhan S, Salamon H, Wang HY, et al. Dynamic antibody responses to the Mycobacterium tuberculosis proteome. Proc Natl Acad Sci USA 2010; 107:14703-8.
92. Steingart KR, Dendukuri N, Henry M, et al. Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis. Clin Vaccine Immunol 2009; 16:260-76.
93. Cobelens et al. Which new diagnostic for tuberculosis, and when? J Infect Dis 2012; 205(Suppl 2):S191-8.
94. Schito et al. Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis. J Infect Dis 2012; 205(Suppl 2):S169-80.